Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Factor VII
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
{{cs1 config|name-list-style=vanc}} {{Short description|Mammalian protein found in humans}} {{Lead rewrite|date=April 2024|reason=More than half of the lead is about recent pharmaceuticals, not the natural protein.}} {{Infobox gene}} '''Coagulation factor VII''' ({{EC number|3.4.21.21}}, formerly known as '''proconvertin''') is a [[protein]] involved in [[coagulation]] and, in humans, is encoded by [[gene]] ''F7''. It is an [[enzyme]] of the [[serine protease]] class. Once bound to [[tissue factor]] released from damaged tissues, it is converted to '''factor VIIa''' (or ''blood-coagulation factor VIIa'', ''activated blood coagulation factor VII''), which in turn activates [[factor IX]] and [[factor X]]. Using [[genetic recombination]] a [[recombinant factor VIIa]] (eptacog alfa) (trade names include NovoSeven) has been approved by the [[FDA]] for the control of bleeding in [[hemophilia]].<ref name="ERH">{{cite journal | vauthors = Biron-Andreani C, Schved JF | title = Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors | journal = Expert Review of Hematology | volume = 12 | issue = 1 | pages = 21–28 | date = January 2019 | pmid = 30577721 | doi = 10.1080/17474086.2019.1560259 | s2cid = 58538425 }}</ref> It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A [[biosimilar]] form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market. In April 2020, the US FDA approved a new rFVIIa product, eptacog beta (SEVENFACT), the first [[bypassing agent]] (BPA) approved in more than 2 decades. As an rFVIIa product, eptacog beta works in a complex with tissue factor to activate factor X to Xa, thereby bypassing FVIII and FIX. The activation of Factor X to Xa initiates the coagulation cascade’s common pathway, leading to clot formation at the site of hemorrhage. Activated FVII binds to endothelial protein C receptor (EPCR), which enhances hemostasis.14 One study showed that eptacog beta binds to EPCR with 25% to 30% more affinity than eptacog alfa, displacing protein C from EPCR binding sites and downregulating activated protein C generation, contributing to its hemostatic effect.
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)